1. Home
  2. FLO vs PGEN Comparison

FLO vs PGEN Comparison

Compare FLO & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flowers Foods Inc.

FLO

Flowers Foods Inc.

HOLD

Current Price

$7.77

Market Cap

1.6B

ML Signal

HOLD

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$4.82

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLO
PGEN
Founded
1919
1998
Country
United States
United States
Employees
10300
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
2000
2013

Fundamental Metrics

Financial Performance
Metric
FLO
PGEN
Price
$7.77
$4.82
Analyst Decision
Hold
Buy
Analyst Count
5
5
Target Price
$11.20
$8.33
AVG Volume (30 Days)
7.1M
4.9M
Earning Date
05-15-2026
05-13-2026
Dividend Yield
11.16%
N/A
EPS Growth
N/A
N/A
EPS
0.20
N/A
Revenue
$5,256,479,000.00
$230,981,000.00
Revenue This Year
N/A
$1,115.92
Revenue Next Year
$0.65
$81.04
P/E Ratio
$38.65
N/A
Revenue Growth
3.00
N/A
52 Week Low
$6.80
$1.40
52 Week High
$16.85
$5.47

Technical Indicators

Market Signals
Indicator
FLO
PGEN
Relative Strength Index (RSI) 51.03 64.27
Support Level $6.80 $3.96
Resistance Level $8.24 $5.06
Average True Range (ATR) 0.32 0.29
MACD 0.05 0.10
Stochastic Oscillator 67.82 94.24

Price Performance

Historical Comparison
FLO
PGEN

About FLO Flowers Foods Inc.

Flowers Foods Inc operates as a producer and marketer of packaged bakery foods in the United States. Its principal products include breads, buns, rolls, snack items (bars, cakes, cookies, and crackers), bagels, English muffins, tortillas, and baking mixes. These products are sold under the brand names Nature's Own, Dave's Killer Bread (DKB), Canyon Bakehouse, Simple Mills, Wonder, and Tastykake. The company derives the majority of its revenue from the sales of its bakery products.

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Share on Social Networks: